Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio 
Welcome,         Profile    Billing    Logout  
 26 Diseases   30 Trials   30 Trials   518 News 


«12345678910111213»
  • ||||||||||  Enrollment change, Trial withdrawal, Metastases:  QUILT-3.088: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) -  Aug 28, 2019   
    P2,  N=0, Withdrawn, 
    N=1064 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Metastases:  QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) -  Aug 28, 2019   
    P1/2,  N=0, Withdrawn, 
    N=1064 --> 0 | Not yet recruiting --> Withdrawn N=382 --> 0 | Trial completion date: Dec 2022 --> Aug 2019 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jul 2020 --> Aug 2019
  • ||||||||||  Anktiva (inbakicept) / ImmunityBio
    Trial completion:  QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803 (clinicaltrials.gov) -  Aug 28, 2019   
    P1,  N=20, Completed, 
    N=382 --> 0 | Trial completion date: Dec 2022 --> Aug 2019 | Active, not recruiting --> Withdrawn | Trial primary completion date: Jul 2020 --> Aug 2019 Active, not recruiting --> Completed
  • ||||||||||  Empliciti (elotuzumab) / AbbVie, BMS
    Trial completion date, Trial primary completion date:  2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) (clinicaltrials.gov) -  Aug 22, 2019   
    P2,  N=10, Not yet recruiting, 
    These findings indicate that ALT-803 can enhance ADCC activity mediated by NEO-201, by modulating NK activation and cytotoxicity, suggesting a possible clinical use of ALT-803 in combination with NEO-201 for the treatment of human carcinomas. Trial completion date: Aug 2019 --> Aug 2021 | Trial primary completion date: Aug 2019 --> Aug 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, ALT-803 / Altor BioScience, NantKwest
    Journal:  An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck. (Pubmed Central) -  Aug 15, 2019   
    Administration of both cetuximab and ALT-803 to mice harboring Cal27 SCCHN tumors resulted in significantly decreased tumor volume when compared to controls and compared to single-agent treatment alone. Overall, the present data suggest that cetuximab treatment in combination with ALT-803 in patients with EGFR-positive SCCHN may result in significant NK cell activation and have important anti-tumor activity.
  • ||||||||||  Anktiva (inbakicept) / ImmunityBio
    Journal:  Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. (Pubmed Central) -  Aug 1, 2019   
    Consistent with this, treatment of a patient with ALT-803 for recurrent CMV reactivation after hematopoietic cell transplant was associated with clearance of viremia. These studies demonstrate that NK cell-mediated control of viral infection requires glucose metabolism and that IL-15 treatment in vivo can reduce this requirement and may be effective as an antiviral therapy.
  • ||||||||||  Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  QUILT-2.005: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) -  Jul 23, 2019   
    P1/2,  N=596, Recruiting, 
    These studies demonstrate that NK cell-mediated control of viral infection requires glucose metabolism and that IL-15 treatment in vivo can reduce this requirement and may be effective as an antiviral therapy. Active, not recruiting --> Recruiting | N=256 --> 596 | Trial completion date: Oct 2019 --> Oct 2021 | Trial primary completion date: Jul 2019 --> Jul 2021
  • ||||||||||  doxycycline / generics
    Journal:  Regulatory effects of Interleukin (IL)-15 on allergen-induced airway obstruction. (Pubmed Central) -  Jul 17, 2019   
    Active, not recruiting --> Recruiting | N=256 --> 596 | Trial completion date: Oct 2019 --> Oct 2021 | Trial primary completion date: Jul 2019 --> Jul 2021 We report our novel finding that IL-15 has a potent inhibitory effect on the airway obstruction that occurs in response to environmental allergens.
  • ||||||||||  Trial completion date, Trial primary completion date:  QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) -  Jul 15, 2019   
    P1b/2,  N=173, Active, not recruiting, 
    Trial primary completion date: May 2019 --> Dec 2019 Trial completion date: May 2020 --> Dec 2019 | Trial primary completion date: May 2019 --> Dec 2019
  • ||||||||||  Enrollment closed, Metastases:  QUILT-3.071: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine (clinicaltrials.gov) -  May 17, 2019   
    P1b/2,  N=332, Active, not recruiting, 
    This immunostimulatory IL-15 superagonist warrants further investigation to augment anti-tumor immunity alone and combined with other immunotherapies. Recruiting --> Active, not recruiting
  • ||||||||||  Enrollment closed:  QUILT-3.080: NANT Pancreatic Cancer Vaccine (clinicaltrials.gov) -  May 13, 2019   
    P1b/2,  N=173, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> May 2019 Recruiting --> Active, not recruiting
  • ||||||||||  Enrollment closed, Metastases:  QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (clinicaltrials.gov) -  May 13, 2019   
    P1/2,  N=382, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Anktiva (inbakicept) / ImmunityBio
    Enrollment open:  Adoptive Transfer of Haploidentical NK Cells and N-803 (clinicaltrials.gov) -  May 2, 2019   
    P1,  N=8, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  NN1213 / Novo Nordisk, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
    Trial completion date, Trial primary completion date:  ALT-803: Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People (clinicaltrials.gov) -  Apr 19, 2019   
    P1,  N=10, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jul 2018 --> Sep 2019
  • ||||||||||  Anktiva (inbakicept) / ImmunityBio
    New P1 trial:  Adoptive Transfer of Haploidentical NK Cells and N-803 (clinicaltrials.gov) -  Apr 2, 2019   
    P1,  N=8, Not yet recruiting, 
  • ||||||||||  Anktiva (inbakicept) / NantWorks
    Journal:  An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression. (Pubmed Central) -  Mar 2, 2019   
    An interleukin (IL)-15 superagonist/IL-15 receptor α fusion complex (IL-15SA/IL-15RA; ALT-803) activates the IL-15 receptor on CD8 T cells and NK cells, and has shown significant anti-tumor activity in several in vivo studies...IL-15SA/IL-15RA blocked Smad2/3-induced transcription, resulting in the rescue of NK cell-cytotoxic function from TGF-β1-induced suppression. These findings suggest that in addition to increasing NK cell function via promoting the IL-15 signaling pathway, IL-15SA/IL-15RA can function as an inhibitor of TGF-β1 signaling, providing a potential remedy for NK cell dysfunction in the immunosuppressive tumor microenvironment.
  • ||||||||||  PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
    Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date, Checkpoint inhibition, MSi-H Biomarker, PD(L)-1 Biomarker:  QUILT-3.055: a Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with Immune Checkpoint Inhibitors (clinicaltrials.gov) -  Feb 8, 2019   
    P2b,  N=611, Recruiting, 
    These findings suggest that in addition to increasing NK cell function via promoting the IL-15 signaling pathway, IL-15SA/IL-15RA can function as an inhibitor of TGF-β1 signaling, providing a potential remedy for NK cell dysfunction in the immunosuppressive tumor microenvironment. N=105 --> 611 | Trial completion date: Aug 2022 --> Aug 2020 | Initiation date: Jun 2018 --> Dec 2018 | Trial primary completion date: May 2021 --> Jun 2020
  • ||||||||||  Anktiva (inbakicept) / NantWorks
    Journal, PD(L)-1 Biomarker, IO biomarker:  The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. (Pubmed Central) -  Feb 5, 2019   
    This molecule comprises the IL-15/IL15Rα superagonist complex containing the Fc-domain of IgG1 (N-803, formerly designated as ALT-803) fused to two single chain anti-PD-L1 domains...Similarly, the highest level of ADCC was seen when both NK cells (from donors or cancer patients) and tumor cells were exposed to N-809. These studies thus demonstrate the multi-functionality of this novel agent.
  • ||||||||||  Opdivo (nivolumab) / BMS, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
    Trial primary completion date:  ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) -  Dec 28, 2018   
    P1/2,  N=91, Recruiting, 
    These data identify a regulatory role for cytokine-stimulated NK cells in the prevention of a pathogenic immune response. Trial primary completion date: Dec 2018 --> Jun 2019